LoneStar Heart Inc.
Addressing heart failure with an injectable biopolymer
This article was originally published in Start Up
LoneStar Heart's injectable biopolymer Algisyl-LVR represents a new advanced HF treatment strategy based on a medically accepted principle that a reduction in muscle tension and wall stress of the dilated heart will improve its function. The company, which originally envisioned Algisyl-LVR as a carrier for targeted delivery of biologics, drugs, or stem cells, discovered in animal studies that use of the biopolymer by itself had a profound effect on improving the mechanics of the heart.
You may also be interested in...
A round-up of developments in the COVID-19 vaccine field from Moderna, Fosun, Merck & Co and Medicago and more.
Until the EU’s MDR expert panels are in place, notified bodies cannot complete conformity assessment of certain high-risk devices. But progress is being made at last.